Your session is about to expire
← Back to Search
Alirocumab for Heart Transplant Rejection
Study Summary
This trial tests whether the drug alirocumab is safe and effective in preventing heart transplant rejection.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 20 Patients • NCT02938949Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver isn't working properly.I have received a heart transplant.
- Group 1: alirocumab
- Group 2: placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the biggest number of enrollees that this trial can have and still be considered successful?
"Unfortunately, this particular study is not currently enrolling patients. The last update on the status of the trial was posted on May 22nd, 2022. However, there are 114 other trials related to vasculopathy and 10 studies involving alirocumab that are still admitting participants."
Can patients currently enroll in this research project?
"Unfortunately, this study is no longer looking for new patients to enroll. Although, it's worth noting that there are 114 other clinical trials still recruiting patients with vasculopathy and 10 more specifically testing alirocumab."
What are the conditions that alirocumab is most effective in treating?
"Alirocumab has shown efficacy in treating myocardial infarction, hypercholesterolemia, and unstable angina pectoris."
Are there any dangers associated with alirocumab that patients should be made aware of?
"Alirocumab has received a score of 2 for safety. Phase 2 trials have yielded some data supporting alirocumab's safety, but there is currently no information regarding the efficacy of this medication."
Is this the first time that alirocumab has been looked at in a scientific setting?
"Currently, there are 10 live clinical trials investigating alirocumab. 1 of those is in Phase 3. While the many trials for alirocumab are based in Chicago, Illinois, there are 12 locations running studies for this treatment."
Share this study with friends
Copy Link
Messenger